

Resource Summary Report

Generated by [RRID](#) on Aug 24, 2026

pcDNA3-sACE2(WT)-8his

RRID:Addgene_149268

Type: Plasmid

Proper Citation

RRID:Addgene_149268

Plasmid Information

URL: <http://www.addgene.org/149268>

Proper Citation: RRID:Addgene_149268

Insert Name: Angiotensin-converting enzyme 2

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:32753553](#)

Vector Backbone Description: Backbone Marker:Invitrogen; Backbone Size:5332; Vector Backbone:pcDNA3.1(+); Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: Please visit <https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1> for BioRxiv preprint.

Plasmid Name: pcDNA3-sACE2(WT)-8his

Relevant Mutation: Extracellular, soluble protease domain (a.a. M1-D615)

Record Creation Time: 20220422T221828+0000

Record Last Update: 20260815T080713+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3-sACE2(WT)-8his.

No alerts have been found for pcDNA3-sACE2(WT)-8his.

Data and Source Information

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Idrovo-Hidalgo T, et al. (2024) Deglycosylated RBD produced in *Pichia pastoris* as a low-cost sera COVID-19 diagnosis tool and a vaccine candidate. *Glycobiology*, 34(1).

Berman K, et al. (2024) Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots. *Microbiology spectrum*, 12(12), e0084624.

Eliadis P, et al. (2024) Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera. *Vaccines*, 12(8).

Rubio AA, et al. (2024) Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern. *bioRxiv : the preprint server for biology*.

Chen C, et al. (2023) hACE2-Induced Allosteric Activation in SARS-CoV versus SARS-CoV-2 Spike Assemblies Revealed by Structural Dynamics. *ACS infectious diseases*, 9(6), 1180.

Sergeeva AP, et al. (2023) Free Energy Perturbation Calculations of Mutation Effects on SARS-CoV-2 RBD::ACE2 Binding Affinity. *Journal of molecular biology*, 435(15), 168187.

Taha Z, et al. (2022) Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen. *Molecular therapy : the journal of the American Society of Gene Therapy*, 30(9), 2998.

, et al. (2022) Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2. *Scientific reports*, 12(1), 692.

Zhang L, et al. (2022) An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. *bioRxiv : the preprint server for biology*.

Zhang L, et al. (2021) Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants. *bioRxiv : the preprint server for biology*.

Procko E, et al. (2020) The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. *bioRxiv : the preprint server for biology*.